GlassScriptPhysician profile
Amie Hellman
NPI 1477852408
$2,604.12
in general payments reported to CMS, 2019-2025
23 companies · $2,586 in 2025
The $2,586 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.26 · 2025: $2,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.38 |
| Education | $134.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $581.53 | 2022-2025 | |
| Ucb, INC. | $253.61 | 2025 | Nayzilam, Rystiggo, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $247.36 | 2025 | Austedo Xr |
| Eisai INC. | $211.20 | 2025 | |
| Pfizer INC. | $177.94 | 2025 | |
| Sk Life Science, INC. | $174.59 | 2025 | Xcopri |
| Neurocrine Biosciences, INC. | $152.11 | 2025 | |
| Novartis Pharmaceuticals Corporation | $109.30 | 2025 | |
| Tg Therapeutics, INC. | $101.59 | 2025 | |
| Neurelis, INC. | $87.91 | 2025 | Valtoco |
| Janssen Biotech, INC. | $72.73 | 2025 | |
| Mallinckrodt Hospital Products INC. | $62.93 | 2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $60.78 | 2025 | Ultomiris |
| Mdd US Operations, LLC | $45.42 | 2025 | Gocovri, Qelbree |
| Emd Serono, INC. | $40.33 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $38.55 | 2025 | Crexont |
| Argenx US, INC. | $36.57 | 2025 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $32.74 | 2025 | Xeomin, Inbrija |
| Axsome Therapeutics, INC. | $28.29 | 2025 | Symbravo |
| Tanabe Pharma America, INC. | $25.47 | 2025 | Radicava |
| Lundbeck LLC | $23.84 | 2025 | Vyepti |
| Impel Pharmaceuticals LLC | $19.93 | 2025 | Trudhesa |
| Lilly USA, LLC | $19.40 | 2025 | Amyvid, Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Hellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.